TMEM267 (Gene)

Organism:

Homo sapiens

Gene:

TARGET ID 09565

Synonyms:C5orf28, ENTREZ:64417, HGNC:26139, NM_001377394, NM_001377395, NM_001377396, NM_001377397, NM_001377398, NM_001377399, NM_001377400, NM_001377401, NM_001377402, NM_001377403, NM_022483, NP_001364323, NP_001364324, NP_001364325, NP_001364326, NP_001364327, NP_001364328, NP_001364329, NP_001364330, NP_001364331, NP_001364332, NP_071928, TMEM267, XM_011514075, XP_011512377, transmembrane protein 267

Id:ENSG00000151881

Hgnc:HGNC:26139

Entrez:64417

Ensembl:ENSG00000151881

Description:transmembrane protein 267

Predicted to be integral component of membrane. [provided by Alliance of Genome Resources, Apr 2022]

Analyze

CFDE DD-Knowledge Graph

The CFDE Data Distillery Knowledge Graph contains entities and relationships across the CFDE. View TMEM267's neighborhood in the knowledge graph.

Submit

Playbook Workflow Builder: Gene-Centric Workflow

View Gene-Centric information about the gene from a pre-built PWB workflow. View the workflow with TMEM267.

CFDE Gene-Centric Appyter

The CFDE Gene Centric Appyter Resolves and Displays Gene-Centric information from CFDE APIs. Execute the Appyter using TMEM267.

Submit

GDLPA Landing Pages Links

The Gene and Drug Landing Page Aggregator (GDLPA) finds links to primary and secondary source information from CFDE and other resources. Discover landing pages for TMEM267.

Submit

Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with TMEM267.

Results found

Linked to

	Label	Description
	GSE138789 metformin 0 v 1 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE158834 ADIPOR2 knockout HEK293 1 v 6 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE169356 ivermectin prostate gland 0 v 1 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE169356 FOXA1 inhibition prostate gland Ivermectin 0 v 1 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE132369,GSE132371 3 V 0 CCCP HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE139987 1 V 2 ROSIGLITAZONE MOUSE DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE206927 PPARG knockdown endothelial cell 2 v 0 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE82032 trametinib HCC1143 3 v 1 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE81796 0 V 2 ENZALUTAMIDE HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE125157 1 V 0 PICEATANNOL MOUSE UP Gene Set (Entity type)	A Gene Set from LINCS

GSE138789 metformin 0 v 1 human up

Gene Set (Entity type)

A Gene Set from LINCS

GSE158834 ADIPOR2 knockout HEK293 1 v 6 human dn

Gene Set (Entity type)

A Gene Set from LINCS

GSE169356 ivermectin prostate gland 0 v 1 human up

Gene Set (Entity type)

A Gene Set from LINCS

GSE169356 FOXA1 inhibition prostate gland Ivermectin 0 v 1 human up

Gene Set (Entity type)

A Gene Set from LINCS

GSE132369,GSE132371 3 V 0 CCCP HUMAN UP

Gene Set (Entity type)

A Gene Set from LINCS

GSE139987 1 V 2 ROSIGLITAZONE MOUSE DN

Gene Set (Entity type)

A Gene Set from LINCS

GSE206927 PPARG knockdown endothelial cell 2 v 0 human up

Gene Set (Entity type)

A Gene Set from LINCS

GSE82032 trametinib HCC1143 3 v 1 human dn

Gene Set (Entity type)

A Gene Set from LINCS

GSE81796 0 V 2 ENZALUTAMIDE HUMAN UP

Gene Set (Entity type)

A Gene Set from LINCS

GSE125157 1 V 0 PICEATANNOL MOUSE UP

Gene Set (Entity type)

A Gene Set from LINCS

DISPLAY PER PAGE

CFDE Workbench

Consortium

Community

Resources

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

Consortium

Community

Resources

CFDE Workbench

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.